Compound ID | 2885
SER-155
Class: Natural product antibiotic
| Details of activity: | Restores unhealthy/altered gut microbiome |
| Description: | Cultivated microbiome made of fermented bacterial species; potentially immunomodulating |
| Institute where first reported: | Seres Therapeutics, Inc. |
| Year first mentioned: | 2022 |
| Highest developmental phase: | Phase 1 (NCT04995653) |
| Development status: | Active as of 2024 |
| External links: | |
| Citation: | https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.TPS7074 |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.